End-Stage Kidney Disease - Pipeline Review, H1 2017

  • ID: 4267359
  • Drug Pipelines
  • 54 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • BLR Bio LLC
  • CTI BioPharma Corp
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • VESSL Therapeutics Ltd
  • MORE
End-Stage Kidney Disease - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide End-Stage Kidney Disease - Pipeline Review, H1 2017, provides an overview of the End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline landscape.

End-stage kidney disease is the complete or almost complete failure of the kidneys to work. Symptoms include inability to urinate, fatigue, headaches, loss of appetite, nausea and vomiting, bone pain, confusion and difficulty concentrating. The risk factors include polycystic kidney disease, Alport syndrome, interstitial nephritis and certain autoimmune conditions, such as lupus. Treatment includes dialysis or kidney transplant.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide End-Stage Kidney Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase I, IND/CTA Filed and Preclinical stages are 1, 4, 1 and 2 respectively.

End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of End-Stage Kidney Disease (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • BLR Bio LLC
  • CTI BioPharma Corp
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • VESSL Therapeutics Ltd
  • MORE
Introduction

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Companies Involved in Therapeutics Development

BLR Bio LLC

CTI BioPharma Corp

F. Hoffmann-La Roche Ltd

Novartis AG

Prolong Pharmaceuticals LLC

VESSL Therapeutics Ltd

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Drug Profiles

BLR-400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

calcium succinate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MultiGeneGraft - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

obinutuzumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pacritinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Plasma Gelsolin Replacement for Renal Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sanguinate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tesidolumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), H1

Number of Products under Development by Companies, H1

Products under Development by Companies, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by BLR Bio LLC, H1

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by CTI BioPharma Corp, H1

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by F. Hoffmann-La Roche Ltd, H1

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Novartis AG, H1

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Prolong Pharmaceuticals LLC, H1

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by VESSL Therapeutics Ltd, H1

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects, H1

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products, H1

List of Figures:

Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), H1

Number of Products under Development by Companies, H1

Number of Products by Targets, H1

Number of Products by Stage and Targets, H1

Number of Products by Mechanism of Actions, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • BLR Bio LLC
  • CTI BioPharma Corp
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Prolong Pharmaceuticals LLC
  • VESSL Therapeutics Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll